Melatonin Ameliorates Abnormal Sleep-Wake Behavior via Facilitating Lipid Metabolism in a Zebrafish Model of Parkinson’s Disease DOI

Meng‐Zhu Pang,

Han-Xing Li,

Xue-Qin Dai

et al.

Neuroscience Bulletin, Journal Year: 2024, Volume and Issue: 40(12), P. 1901 - 1914

Published: Sept. 16, 2024

Language: Английский

Alteration of circadian sleep-wake rhythm and salivary melatonin secretion in idiopathic/isolated REM sleep behavior disorder: Preliminary evidence DOI
Matteo Carpi, Mariana Fernandes,

Irene Risino

et al.

Sleep Medicine, Journal Year: 2024, Volume and Issue: 119, P. 135 - 138

Published: April 17, 2024

Language: Английский

Citations

5
Assessment of the Efficacy and Safety of Sublingual Melatonin on Symptom Severity, Quality of Life, and Sleep Disorders in Patients with Irritable Bowel Syndrome DOI Creative Commons
Shabnam Shahrokh,

Niloofar Namazi,

Mohammad Abbasinazari

et al.

Deleted Journal, Journal Year: 2025, Volume and Issue: 24(1)

Published: Feb. 15, 2025

Background: Previous studies have demonstrated the efficacy of melatonin in alleviating symptoms irritable bowel syndrome (IBS) and improving quality life (QoL). Objectives: Due to its superior bioavailability, this trial was designed compare effects sublingual (SL melatonin) with a placebo IBS symptoms, enhancing QoL, addressing sleep disorders. Methods: The patients were randomly assigned receive either 3 mg SL or matching for eight weeks. Participants completed symptom severity score (IBS-SSS), IBS-quality 34 items (IBS-QoL 34), Pittsburgh Sleep Quality Index (PSQI) questionnaires immediately before after study period. Results: A total 76 over six months. results indicated that QoL scores significantly better group compared (P = 0.032 P 0.045, respectively). No participants withdrew from due serious side groups. Conclusions: Sublingual may be administered as complementary treatment alleviate improve QoL.

Language: Английский

Citations

0
Melatonin Regulates Glymphatic Function to Affect Cognitive Deficits, Behavioral Issues, and Blood–Brain Barrier Damage in Mice After Intracerebral Hemorrhage: Potential Links to Circadian Rhythms DOI Creative Commons

Yunzhao Chen,

Huifang Guo,

Xinguo Sun

et al.

CNS Neuroscience & Therapeutics, Journal Year: 2025, Volume and Issue: 31(2)

Published: Feb. 1, 2025

ABSTRACT Background Intracerebral hemorrhage (ICH) is a life‐threatening cerebrovascular disorder with no specific pharmacological treatment. ICH causes significant behavioral deficits and cognitive impairments. Recent research suggests that circadian rhythm regulation could be promising therapeutic strategy for ICH. Melatonin has been shown to alleviate glymphatic system (GS) dysfunction by regulating rhythms, thereby improving depressive‐like behaviors postoperative sleep disorders in mice. However, its application treatment mechanisms are not well understood. Methods models were created 8‐to‐10‐week‐old mice using collagenase injection. Circadian modulation was tested melatonin luzindole. Behavioral impairments assessed the modified neurological severity score, corner test, novel object recognition test. Brain water content measured dry/wet weight method, cerebral perfusion blood flow measurements. GS function evaluated RITC‐dextran Evans blue assays. Immunofluorescence western blotting used analyze BBB permeability. Results restored transport after ICH, promoting hematoma edema absorption, reducing damage, outcomes. luzindole partially blocked these benefits reversed neuroprotective effects. Conclusion affect function, permeability, cognitive‐behavioral outcomes The underlying mechanism may involve of rhythms.

Language: Английский

Citations

0
Neuroprotective Potential of Melatonin: Evaluating Therapeutic Efficacy in Alzheimer's and Parkinson's Diseases DOI Open Access
Norris C Talbot,

Patrick M. Luther,

Noah J Spillers

et al.

Cureus, Journal Year: 2023, Volume and Issue: unknown

Published: Dec. 22, 2023

Decreased melatonin levels have been linked to both Alzheimer's disease (AD) and Parkinson's (PD), which are the two most prevalent neurodegenerative disorders. The development of sleep disorders is widespread in patients diagnosed with AD or PD. In this regard, calcification pineal gland, typically seen third decade, has associated a reduction production. Recent studies suggested that exogenous application can be utilized treat diseases. Furthermore, research shown deficiencies PD begin before diagnosis either made. These findings could encourage further on as potential biomarker for possible area early treatment these Many clinical also produced data denoting method reduce detrimental neurocognitive effects Further role diseases expand symptomatic prophylactic options such This review investigates melatonin's physiological properties, its PD, current therapeutic benefits patients.

Language: Английский

Citations

9
Associations between self‐reported parasomnias and psychiatric illness in 370,000 patients with sleep disorders DOI Open Access
Umaer Hanif, Alyssa Cairns, Vincent Mysliwiec

et al.

Psychiatry and Clinical Neurosciences, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 30, 2024

To assess self-reported parasomnias in patients with sleep disorders and explore relationships psychiatric illness, comorbidities, subjective assessments, polysomnographic study results.

Language: Английский

Citations

2
REM Behavior Disorder: Implications for PD Therapeutics DOI
Jeanne Feuerstein, Amy W. Amara

Current Neurology and Neuroscience Reports, Journal Year: 2023, Volume and Issue: 23(11), P. 727 - 734

Published: Oct. 13, 2023

Language: Английский

Citations

3
Melatonin Ameliorates Abnormal Sleep-Wake Behavior via Facilitating Lipid Metabolism in a Zebrafish Model of Parkinson’s Disease DOI

Meng‐Zhu Pang,

Han-Xing Li,

Xue-Qin Dai

et al.

Neuroscience Bulletin, Journal Year: 2024, Volume and Issue: 40(12), P. 1901 - 1914

Published: Sept. 16, 2024

Language: Английский

Citations

0